Nodular Liver a Marker for Worse Outcomes in Cystic Fibrosis Liver Disease
Researchers sought to determine the long-term clinical outcomes in children with nodular liver in cystic fibrosis.
All articles by Jessica Nye, PhD
AGA Clinical Practice Update on Endoscopy in Recurrent Acute, Chronic Pancreatitis
Endoscopic ultrasound remains the preferred diagnostic method for unexplained recurrent acute pancreatitis. Credit: Shutter Stock
Funding Substance Use Treatment via Medicaid Fee-For-Service May Increase Access
Researchers examined the association between changes in Medicaid managed care plan coverage for substance use services and admissions for substance use treatment.
ACC Recommendations on the Role of Nonstatin Therapies for Lowering LDL-C
In 2021, an expert panel assembled to review gaps in care related to treatments meant to lower LDL-C in patients with atherosclerotic cardiovascular disease.
A Case of Myocarditis Observed in a Patient With Monkeypox Infection
It has been found that the monkeypox infection may cause heart problems, including acute myocarditis.
Type 2 Diabetes in Parkinson Disease Associates With Neuroaxonal Damage
Letter authors sought to evaluate the relationship between diabetes mellitus and neurofilament light concentrations in a subgroup of participants in the MARK-PD study.
Guidelines for Managing HF in Diabetes, Cardiorenal, and Metabolic Conditions
Practice guidelines have been developed regarding management of patients with heart failure and diabetes, cardiorenal, and/or metabolic conditions.
AHA Statement on the Effects of Loneliness, Isolation on Cardiovascular Health
The AHA assessed existing research on the impact of loneliness and isolation on brain and cardiovascular health.
Mobile Health Intervention Increases Activity Among Adults With HF and Diabetes
Researchers sought to assess the effectiveness of a mobile health intervention for patients with heart failure and diabetes.
SGLTi Therapy Decreases Long-Term CVD and End-Stage Kidney Disease Risk in Type 1 Diabetes
A study was conducted to determine if SGLT2 inhibitors decrease risk for end-stage kidney disease or cardiovascular disease in patients with type 1 diabetes.
- Loading...
Loading...
Next post in Type 1 Diabetes
Loading... 
Loading...